Semaglutide is a prescription medication for diabetes and weight loss, a weekly injection or daily tablet copying an appetite-controlling gut hormone. In adults with excess weight, diabetes, or heart or kidney disease, strong evidence shows weight loss, fewer heart attacks and strokes, slower kidney decline and longer survival. In lean, healthy adults, benefit is uncertain. Digestive side effects are common, some weight lost is muscle, and benefits fade after stopping. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track percentage change from own baseline | Primary efficacy marker |
| Lean mass (DXA) | No established target; track lean-mass share of total weight lost | Excessive lean loss |
| HbA1c | 4.0–5.6% | Expected to change |
| Fasting glucose | 70–99 mg/dL | Hypoglycemia with insulin or sulfonylureas |
| Blood pressure | Below 130/80 mm Hg | Expected to change; safety on blood-pressure medicines |
| Resting heart rate | 60–100 beats per minute | Label reports increases |
| Creatinine with eGFR | Creatinine 0.59–1.04 mg/dL (women), 0.74–1.35 mg/dL (men) | Dehydration-related acute kidney injury |
| hs-CRP | No established target; track change from own baseline | Expected to change |
| TSH (levothyroxine users on oral tablets) | 0.4–4.0 mIU/L | Oral semaglutide raises thyroxine exposure |
Cadence: Baseline before starting; weight, side effects and glucose (if on insulin or sulfonylureas) every 4 weeks during dose escalation; labs at 3 months, then every 6–12 months; DXA every 6–12 months during active weight loss; kidney function promptly after severe vomiting or diarrhea